Erratum: Inhibition of constitutive activity of nuclear transcription factor kappaB sensitizes doxorubicin-resistant cells to apoptosis (Journal of Cellular Biochemistry (2009) 107 (203-213) DOI: 10.1002/jcb.22115);Inhibition of constitutive activity of nuclear transcription factor kappaB sensitizes doxorubicin-resistant cells to apoptosis

Journal of Cellular Biochemistry

Volumn 107, Issue 2, 2009, Pages 203-213

  Gangadharan, Charitha ^a   Thoh, Maikho ^a   Manna, Sunil K ^a  

^a CENTRE FOR DNA FINGERPRINTING AND DIAGNOSTICS   (India)

Author keywords

Apoptosis; Doxorubicin; Drug resistance; NF B; P3 25

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; CYCLOOXYGENASE 2; DOXORUBICIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LUCIFERASE; MULTIDRUG RESISTANCE PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; REACTIVE SULFUR SPECIES; SYNAPTOTAGMIN I;

APOPTOSIS; ARTICLE; CELL ACTIVITY; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DRUG RESISTANCE; ENZYME DEGRADATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LIPID PEROXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; SENSITIZATION; WILD TYPE;

EID: 66149116716     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24257     Document Type: Erratum

References (34)

1. Anddrassy M, Bierhaus A, Hong M, Sis J, Schiekofer S, Humpert P, Chen J, Haap M, Renn W, Schleicher E, Haring HU, Andrassy K, Nawroth PP. 2002. Erythropoietin-mediated decrease of the redox-sensitive transcription factor NF-κB is inversely correlated with the hemoglobin level. Clin Nephrol 58:179-189.
2. Barre B, Perkins ND. 2007. A cell cycle regulatory network controlling NF-κB subunit activity and function. EMBO J 26:4841-4855.
3. Blum RH, Carter SK. 1974. Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 80:249-259.
4. Bonizzi G, Karin M. 2004. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25:280-288.
5. Chen JS, Agarwal N, Mehta K. 2002. Multidrug-resistant MCF-7 breast cancer cells contain deficient intracellular calcium pools. Breast Cancer Res Treat 71:237-247.
6. Christman JW, Lancaster LH, Blackwell TS. 1998. Nuclear factor kB: A pivotal role in the systemic inflammatory response syndrome and new target for therapy. Inten Care Med 24:1131-1138.
7. Chuang SE, Yeh PY, Lu YS, Lai GM, Liao CM, Gao M, Cheng AL. 2002. Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappa B, and its attenuation by tamoxifen dexamathasone and curcumin in carcinoma cells. Biochem Pharmacol 63:1709-1716.
8. Cusack J, Liu R, Baldwin A. 1999. NF-κB and chemoresistance: Potentiation of cancer chemotherapy via inhibition of NF-κB. Drug Resist Updates 2:271-273.
9. Deng L, Lin-Lee YC, Claret FX, Kuo MT. 2001. 2-Acetylaminofluorene upregulates rat mdr1b expression through generating reactive oxygen species that activate NF-kappa B pathway. J Biol Chem 276:413-420.
10. Devarajan E, Chen J, Multani AS, Pathak S, Sahin AA, Mehta K. 2002. Human breast cancer MCF-7 cell line contains inherently drug-resistant subclones with distinct genotypic and phenotypic features. Int J Oncol 20:913-920.
11. Fischer UM, Antonyan A, Bloch W, Mehlhorn U. 2006. Impact of antioxidative treatment on nuclear factor kappa-B regulation during myocardial ischemia-reperfusion. Interact Cardiovasc Thorac Surg 5:531-535.
12. Giri DK, Aggarwal BB. 1998. Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. J Biol Chem 273:14008-14014.
13. Harris GR, Morrow M, Bonnadona G. 1993. Cancer of the breast. Philadelphia, Pennsylvania: Lippincott. pp. 1264-1332.
14. Hayden MS, Ghosh S. 2004. Signaling to NF-κB. Gene Dev 18:2195-2224.
15. Jin W, Scotto KW, Hait WN, Yang JM. 2007. Involvement of CtBP1 in the transcriptional activation of the MDR1 gene in human multidrug resistant cancer cells. Biochem Pharmacol 74:851-859.
16. Jobin C, Sartor RB. 2000. The IκB/NF-κB system: A key determinant of mucosa inflammation and protection. Am J Physiol Cell Physiol 278:C451-C562.
17. Jurisicova A, Lee HJ, D'Estaing SG, Tilly J, Perez GI. 2006. Molecular requirements for doxorubicin-mediated death in murine oocytes. Cell Death Diff 13:1466-1474.
18. Kalivendi SV, Konorev EA, Cunningham S, Vanamala SK, Kaji EH, Joseph J, Kalyanaraman B. 2005. Doxorubicin activates nuclear factor of activated T-lymphocytes and Fas ligand transcription: Role of mitochondrial reactive oxygen species and calcium. Biochem J 389:527-539.
19. Kuo MT, Liu Z, Wei Y, Lin-Lee YC, Tatebe S, Mills GB, Unate H. 2002. Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling. Oncogene 21:1945-1954.
20. Manna SK, Aggarwal BB. 1999. Lipopolysaccharide inhibits TNF-induced apoptosis: Role of nuclear factor-kappaB activation and reactive oxygen intermediates. J Immunol 162:1510-1518.
21. Manna SK, Zhang HJ, Yan T, Oberley LW, Aggarwal BB. 1998. Overexpression of Mn-superoxide dismutase suppresses TNF induced apoptosis and activation of nuclear transcription factor-B and activated protein-1. J Biol Chem 273:13245-13254.
22. Manna SK, Kuo MT, Aggarwal BB. 1999. Overexpression of glutamylcysteine synthetase abolishes tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-B and activator protein-1. Oncogene 18:4371-4382.
23. Manna SK, Mukhopadhyay A, Aggarwal BB. 2000. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: Potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 164:6509-6519.
24. Manna SK, Manna P, Sarkar A. 2007. Inhibition of RelA phosphorylation sensitizes chemotherapeutic agents-mediated apoptosis in constitutive NFkappaB-expressing and chemoresistant cells. Cell Death Diff 14:158-170.
25. Mikami T, Koyama T, Koyama T, Imakiire A, Yamamoto K, Furuhata M, Toyota H, Mizuguchi J. 2006. c-Jun N-terminal kinase activation is required for apoptotic cell death induced by TNF-related apoptosis-inducing ligand plus DNA-damaging agents in sarcoma cell lines. Anticancer Res 26:1153-1160.
26. Mori N, Yamada Y, Ikeda S, Yamasaki Y, Tsukasaki K, Tanaka Y, Tomonaga M, Yamamoto N, Fujii M. 2002. Bay 11-7082 inhibits transcription factor NFκB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood 100:1828-1834.
27. Reynoldsa CP, Maurer BJ, Kolesnick RN. 2004. Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett 206:169-180.
28. Rojo AI, Salinas M, Martin D, Perona R, Cuadrado A. 2004. Regulation of Cu/Zn-superoxide dismutase expression via the phosphatidylinositol 3 kinase/Akt pathway and nuclear factor-κB. J Neurosci 24:7324-7334.
29. Sarkar A, Sreenivasan Y, Ramesh GT, Manna SK. 2004. Beta-D-glucoside suppresses TNF-induced activation of nuclear transcription factor kappaB but potentiates apoptosis. J Biol Chem 279:33768-33781.
30. Shimokawa I. 2004. Oxidative stress and calorie restriction. Geriatrics Gerontol Int 4:S149-S151.
31. Sreenivasan Y, Sarkar A, Manna SK. 2003. Oleandrin suppresses activation of nuclear transcription factor-kappaB and activator protein-1 and potentiates apoptosis induced by ceramide. Biochem Pharmacol 66:2223-2239.
32. Verma A, Mehta K. 2007. Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug Resist Update 10:144-151.
33. Wang CY, Guttridge DC, Mayo MW, Baldwin AS, Jr. 1999a. NF-κB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 19:5923-5929.
34. Wang CY, Cusack J, Liu R, Baldwin A. 1999b. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 4:412-417.